Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Artigo
em Inglês
| IMSEAR
| ID: sea-88564
ABSTRACT
The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95% of the patients.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Qualidade de Vida
/
Pressão Sanguínea
/
Proteínas Recombinantes
/
Idoso
/
Humanos
/
Hemoglobinas
/
Estudos Prospectivos
/
Seguimentos
/
Eritropoetina
/
Diálise Renal
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
/
Fatores de risco
Idioma:
Inglês
Ano de publicação:
1995
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS